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ABSTRACT 
 
Background & Objective: Chronic Kidney Disease (CKD) is emerging as an important 
public health problem across the world. In severe cases, the disease progresses 
towards end stage renal disease (ESRD) which is associated with several complications. 
In recent years, 25 (OH) Vitamin D has been identified as a risk factor for ESRD. Vitamin 
D plays a vital role in regulating parathyroid hormone (PTH) synthesis and release. 
Decreased Vitamin D levels are identified as a risk factor for secondary 
hyperparathyroidism (SHPT) which is one of the major complications of CKD and is 
associated with renal osteodystrophy. The present study was planned to assess the 
status of 25 (OH) Vitamin D and its role in secondary hyperparathyroidism in patients 
with CKD. Materials and Methods: The study was conducted on 50 diagnosed cases of 
CKD (stage 4 and 5), age < 60 years. Age and sex matched healthy subjects (n = 50) 
constituted the control group. Serum 25(OH) Vitamin D and iPTH were estimated for 
all the enrolled subjects. BMI and eGFR were also calculated. All variables were 
compared among the control and diseased group. Results: Vitamin D levels were 
significantly low in the CKD group as compared to the control group (p<0.001). 72% of 
the total CKD patients were deficient in Vitamin D levels. Serum iPTH was significantly 
higher in the CKD patients (p = 0.000). A significant negative correlation was observed 
between iPTH and Vitamin D (r = -0.614).Conclusion: The study suggests that patients 
of CKD are at high risk of Vitamin D deficiency. Vitamin D deficiency has a strong 
association with the pathogenesis of SHPT. 
 
KEYWORDS: Chronic Kidney Disease, Vitamin D, Parathyroid hormone, Secondary 
Hyperparathyroidism, End Stage Renal Disease. 
 
INTRODUCTION 
In the last few decades, chronic kidney disease (CKD) has 
emerged as a global health problem of epidemic proportions. 
It has a major effect on healthcare costs and world 
productivity, particularly in developing countries where the 
young people are the most afflicted population. Although in 
many persons CKD remains an asymptomatic pathologic 
condition that progresses slowly. For many others, CKD 
represents a progressive irreversible process that ultimately 
requires renal replacement therapy. The burden of CKD 
includes not only progression to end-stage renal disease 
(ESRD), but also complications related to renal impairment 
and increased risk of cardiovascular diseases[1]. Cardiovascular 
disease events are the leading cause of morbidity and 
mortality in patients with CKD. Left ventricular hypertrophy 
and vascular calcification are more prevalent among patients 
with CKD.  Additionally, hyperparathyroidism and 
hypovitaminosis D are independent risk factors for vascular 
calcification[2, 3].  
With the growing global epidemic of traditional risk factors like 
hypertension and diabetes in particular, the prevalence of CKD 
and kidney failure is rising continuously[4, 5]. In the past ten 
years, the incidence and prevalence of end-stage renal disease 
have doubled and expected to continue to rise steadily in the 
future. In addition to the well-known risk factors; several 
“nontraditional” risk factors may contribute to the progression 
as well as higher risk of death in patients with CKD compared 
to the general population [1, 6-8]. The increased morbidity and 
mortality related to CKD may be reduced with early detection 
and effective management of risk factors to prevent or delay 
further progression of renal dysfunction and its associated 
complications. 
In recent years, vitamin D deficiency has been recognized as a 
prominent feature of CKD. Growing evidences suggest that 
progression of CKD and many of the secondary complications 
like disturbance in bone mineral metabolism, inflammation, 
cardiovascular disease, anemia and neuropathy may be linked 
to vitamin D [1, 3, 6-8]. In-vitro studies indicate that vitamin D 
besides maintaining bone mineral homeostasis, involved in a 
wide range of physiological functions, including regulation of 
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cytokines, inflammatory and fibrotic pathways, the rennin-
angiotensin system, vascular and cardiac cell function, 
immune response modulation, cell growth and 
differentiation[9-12].  
The data from experimental and clinical studies suggest that 
vitamin D protects kidney by targeting two major pathways: the 
local RAS and the NF-kB pathways that promote renal damage 
and progression of kidney disease[13, 14]. 
Deficiency of vitamin D has been identified as a risk factor for 
end-stage renal disease and co-existing cardiovascular 
disease, and overall mortality in patients with CKD[15, 16]. 
Additionally, vitamin D deficiency causes an increase in 
parathyroid hormone, which increases insulin resistance and 
is associated with diabetes, hypertension, inflammation, and 
cardiovascular risk[17]. 
Secondary hyperparathyroidism is a common and major cause 
for concern as high PTH is associated with the development of 
renal osteodystrophy and cardiovascular complications[3]. In a 
recent study serum iPTH level ≥ 400 pg/ml is identified as an 
independent risk factor for high radial artery intimal 
thickness[2]. Epidemiological studies have also shown that 
damage of large arteries is a major contributing factor to 
morbidity and mortality in patients with CKD and in those with 
ESRD[18]. 
Therefore, the present study was planned to investigate the 
association of 25(OH) vitamin D with secondary 
hyperparathyroidism in patients with chronic kidney disease 
(CKD). 
MATERIAL & METHOD  
Study design: Case control analytical study  
Ethics approval: The study was conducted after seeking 
approval from the institutional ethics committee and 
informed consent was on obtained from the participants  
Sampling method: Consecutive sampling method  
Sample size: In each group 50 participants  
Locus of study: Department of Nephrology, Mahatma Gandhi 
Medical College and Hospital, Jaipur 
Time frame: during May to November 2015. 
Inclusion criteria: Fifty diagnosed cases of CKD (stage 4 and 5) 
as per the guidelines of National Kidney Foundation [19], age up 
to 60 years. Fifty age and sex matched healthy subjects 
constituted the control group. 
Exclusion criteria: Patients with acute renal failure, Primary 
hyperparathyroidism, thyroid or parathyroid surgeries and on 
Vitamin D supplementation were excluded from the study.  
Grouping: Group 1: CKD patients, Group 2: Control  
Methodology: All participants underwent physical 
examinations including anthropometric assessments and 
biochemical assessments. Patient’s medical records were also 
reviewed for history of hypertension, diabetes and other 
associated co-morbidities. Blood samples were collected using 
standard aseptic technique and analyzed for Serum Urea, 
Creatinine, Uric acid by dry chemistry on VITROS 4600 and 
25(OH) Vitamin D and iPTH by CLIA[20] on VITROS ECI. eGFR was 
calculated using Cockeroft and Gault formula.GFR is the best 
measure of the kidneys functioning level. It is calculated based 
on blood creatinine level, age, race, gender and other 
contributing factors. 
Statistical Analysis: Results obtained were analyzed using a 
statistical package program (SPSS 17 Inc; Chicago II, USA) for 
social science. Data were presented as mean ± SD and 
subjected to statistical analysis. P-value < 0.05 was considered 
as statistically significant. All variables were presented in the 
two groups as mean + SD and compared by applying 
student’s‘t’ test (Table 1). 
RESULTS 
Variables CKD patients Control  tvalue P-value 
Age (years) 38.98± 10.32 38.28± 13.72 0.29 NS 
BMI (kg/m2) 20.90± 2.52 21.36± 3.39 0.77 NS 
eGFR (ml/min) 14.3± 4.2 106.37± 13.0 - 48 0.000 
S. Urea (mg/dl) 109.3± 48.3 26.32± 5.17 12.1 0.001 
S.Creatinine 
(mg/dl) 
8.56± 2.9 0.72 ± 0.13 19.1 0.000 
S.Uric acid 
(mg/dl) 
7.87 ± 2.57 4.22 ± 1.47 8.71 0.000 
25(OH)VitaminD 
(ng/ml) 
19.29± 10.77 39.37 ± 10.8 - 9.3 0.000 
S. iPTH (pg/ml) 301.7± 218.2 41.19± 16.2 8.44 0.000 
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Mean age of CKD patients (38.980 ± 10.32 years) was 
comparable with healthy subjects. Body mass index in CKD 
group (20.90 kg/m2) was comparable with healthy subjects 
(21.36kg/m2). As anticipated, mean eGFR was significantly 
lower (14.31± 4.19 ml/min) in CKD group (p<0.000). The mean 
values of renal profile parameters were further compared in 
the CKD and control group. All parameters viz. urea, creatinine 
and uric acid were significantly higher in CKD patients as 
compared to healthy subjects. The mean serum 25-
hydroxyvitamain D level was also observed to be significantly 
lower (p<0.001) in CKD patients (19.29± 0.77 ng/ml) as 
compared to healthy subjects (39.37±10.801 ng/ml). 
The CKD patient group was further subdivided on the basis of 
concentration of 25-hydroxy vitamin D levels (Table 2). It was 
observed that 72% of the subjects were in the “deficient” 
group (< 20 ng/ml). The “insufficient” group (20-<30 ng/ml) 
included 12% of the total patients while only 16 % were having 
“normal” (>30 ng/ml) Vitamin D levels. 
Mean serum iPTH levels were significantly higher in CKD 
population (301.77 ± 218.17 pg/ml) as compared to age-
matched healthy subjects with normal kidney function (41.19 
± 16.21 pg/ml). To evaluate the association between Serum 
iPTH levels and Vitamin D levels, Pearson’s correlation was 
applied. A significant negative correlation (r=-0.614; p=0.000) 
was observed between the two variables. This confirms that 
Vitamin D deficiency plays a major role in the development of 
secondary hyperparathyroidism (SHPT). 
Table 1: Distribution of variables between CKD patients and 
Control group 
Page 7 
Yogi et al.,  
Table 2: Distribution of CKD patients on the basis of 25 (OH) 
Vitamin D levels 
25(OH) Vitamin D 
(ng/ml) 
CKD Patients 
No. of  cases(n) % 
Deficiency <20 ng/ml 36 72 
Insufficiency 20-<30 ng/ml 6 12 
Normal 30-100 ng/ml 8 16 
Total 50 100 
 
Figure 1: Correlation of serum 25(OH) vitamin D with iPTH 
levels 
 
DISCUSSION  
Serum creatinine is the most commonly used marker for 
assessing kidney functions in patients with chronic kidney 
disease. GFR uses the creatinine level and additional factors to 
provide a better estimate of kidney function. The use of serum 
urea is recommended by the Kidney Disease Outcome Quality 
Improvement clinical practice guideline to assess dialysis 
clearance. Recently, uric acid has also been resurrected as a 
potential contributory risk factor in the development and 
progression of CKD [21]. Pilot studies also suggest that lowering 
plasma uric acid concentrations may slow the progression of 
renal disease in subjects with CKD[22-24]. For the present study, 
the renal function variables including eGFR were significantly 
higher in the CKD patient group. 
Findings of the study suggest that prevalence of vitamin D 
deficiency or insufficiency is high among patients with CKD, 
which is in accordance with previous studies[25, 26]. Several 
factors are involved in determining the vitamin D status of an 
individual. In patients with CKD, severely impaired renal 
function, proteinuria/ albuminuria and uremia increase the 
risk of low serum 25(OH) Vitamin D[25]. Gonzalez EA et al 
2004[27] reported 86% prevalence of 25(OH) D deficiency/ 
insufficiency in pre-dialysis patients with normal glomerular 
filtration rate (eGFR) and 97% in patients on dialysis. In 
addition to a high prevalence of 25 (OH) D deficiency or 
insufficiency, patients with CKD also demonstrate profound 
reductions in 1,25(OH)2 D levels, especially those reaching  
ESRD. Decreased renal 1-α hydroxylase activity is the primary 
cause, and this activity is not only affected by the reduction of 
functional renal mass, it is also suppressed by hyperuricemia, 
metabolic-acidosis and uremic toxins disorders commonly 
seen in   advanced CKD[26, 28]. Under normal circumstances, the 
synthesis of 1,25(OH)2D is not substrate (25[OH]D) dependent; 
however, in CKD patients, renal 1α-hydroxylase becomes 
substrate (25[OH]D) dependent, and a higher concentration of 
precursor 25(OH)D is likely needed to reach adequate 
1,25(OH)2D levels [29]. The data from experimental and clinical 
studies suggest that vitamin D protect the kidney by targeting 
two major pathways that promote renal damage and 
progression of kidney disease: the local RAS and the NF-kB 
pathway[13]. 
The study observed a significant negative correlation between 
Vitamin D and iPTH levels in the CKD patients. This observation 
is in accordance with previous studies conducted on CKD 
patients[3, 16, 30, 31]. PTH secreted from parathyroid glands 
maintain the correct balance of calcium and phosphorous in 
the body. PTH is involved in the homeostasis of bone 
metabolism by regulating the level of calcium in the blood, 
release of calcium from bone, absorption of calcium from the 
intestine, and excretion of calcium in the urine. Consequently, 
the levels of calcium and other minerals involved in bone 
metabolism, such as phosphorus and vitamin D, affect the 
secretion of PTH by the parathyroid gland. The findings of 
current study indicate that patients with long standing CKD are 
at high risk of vitamin D deficiency which is further a major 
contributor in the pathogenesis of SHPT.  
Secondary hyperparathyroidism develops universally in 
patients with CKD, especially those on long-term dialysis 
therapy[32]. It is characterized by excessive secretion of 
parathyroid hormone (PTH) and parathyroid hyperplasia, 
resulting in bone disorder, soft tissue calcification and 
significantly increased risk of morbidity and mortality. It is well 
accepted that development of parathyroid hyperplasia is 
associated with down-regulation of the vitamin D receptor 
(VDR) and the calcium-sensing receptor (CaSR)[33]. As kidney 
disease progresses, parathyroid VDR and CaSR levels decrease 
in parallel with the severity of parathyroid hyperplasia[34]. 
Recently, enhanced parathyroid expression of the potent growth 
promoter transforming growth factor alpha (TGF-α) and its 
receptor, the epidermal growth factor receptor (EGFR), has 
been identified as one of the main causes of parathyroid 
hyperplasia and the reduction of VDR in CKD[35].  
1,25 (OH)2 D deficiency promotes parathyroid gland growth 
(hyperplasia) and increased PTH synthesis through loss of the 
ability to up regulate vitamin D receptor expression within 
parathyroid cells[36]. The end result is elevated serum PTH and 
abnormal calcium (Ca) and phosphorus (P) balance. The 
combination of persistently high PTH and low 1,25- (OH)2  D is 
associated with bone loss, cardiovascular disease, immune 
suppression and increased mortality in patients with end-
stage kidney failure. 
Elevated PTH and hyperphosphatemia were recently 
identified as risk factors for mortality in dialysis patients[37]. 
Clinical data indicates that vitamin D treatment is an important 
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factor that may mitigate the effects of SHPT and 
hyperphosphatemia on cardiovascular mortality. Deficiency of 
vitamin D is not only limited to the active hormone, calcitriol but 
calcidiol (25- hydroxycholecalciferol) is also deficient in most 
patients with chronic kidney disease (CKD), independent of 
their underlying renal function. Decrease in calcitriol occurs 
relatively early in the progression of kidney disease and may 
predate the increase in PTH. These changes in calcitriol and 
PTH contribute to the maintenance of relatively normal serum 
calcium concentrations until the GFR decreases to <20–25%; 
however, the result is the potential development of bone and 
vascular disease. 
The findings of the above study suggest that patients of CKD 
are at risk of developing hypovitaminosis D due to several 
interrelated complex processes. The hydroxylation of Vitamin 
D to Vitamin D3 (1,25-dihydroxy Vitamin D) occurs in renal 
tissue, therefore deficiency of D3 becomes obvious in CKD 
patients. However, a reduction in the levels of 25(OH) Vitamin 
D is a matter of concern for clinicians as well as research 
personnel. The present study reported a highly significant 
negative correlation between Vitamin D and iPTH levels. This 
indicates that with fall of Vitamin D levels, the risk of 
developing SHPT increases which itself is a risk factor for ESRD. 
The study therefore, recommends further research on the 
effect of renal dysfunction and hyperparathyroidism on other 
markers of bone development and mineralization viz. Calcium, 
Phosphorus, Alkaline phosphatase, Calcitonin etc. 
The balance of calcium, phosphorus, vitamin D, and iPTH is 
complex and interrelated. So patients must adhere to dietary 
restrictions, therapies, and complicated medication regimens. 
These factors create barriers to achieving and maintaining 
control of SHPT. 
CONCLUSION  
The findings of the above study suggest that patients of CKD 
are at risk of developing hypovitaminosis D. There was highly 
significant negative correlation between Vitamin D and iPTH 
levels. The study recommends routine screening for Vitamin D 
levels in patients of CKD. Identification of patients with low 
Vitamin D levels will be helpful in timely management of the 
patients as well as minimizing the risk of associated 
complications. 
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